Why the FDA Removed Semaglutide From Shortage and What Happened Next

The FDA ended the semaglutide shortage in February 2025 and the tirzepatide shortage in December 2024. Here's what those two determinations set in motion and why the compounded GLP-1 era ended.

For roughly three years, semaglutide was on the FDA's official drug shortage list. That single regulatory status enabled an entire industry: 503A and 503B compounding pharmacies were legally permitted to produce essentially-copy versions of Wegovy and Ozempic while the brand-name products couldn't keep up with demand. Telehealth companies built nine-figure businesses on top of that arrangement.

In February 2025, the FDA declared the semaglutide shortage resolved. In December 2024, it had done the same for tirzepatide. Those two announcements set in motion everything that followed — the warning letters, the Novo-Hims deal, the collapse of mass-market compounded GLP-1 distribution, and the pivot to brand-name authorized telehealth.

What "Shortage Resolved" Actually Means

The FDA's drug shortage program is governed by specific criteria defined in federal law. A drug is considered in shortage when the total supply across all manufacturers is insufficient to meet current or projected demand at the patient level. A drug is considered resolved when manufacturers have reported sufficient production to meet that demand and the agency has verified availability through its monitoring process.

The resolution determination is not a policy preference or an industry concession — it is a statutory finding based on reported production volumes, pharmacy fulfillment data, and patient access reports. Once a drug is declared no longer in shortage, the 503B outsourcing-facility exception for essentially-copy compounding no longer applies.

Why the Shortage Ended When It Did

Novo Nordisk invested massively in manufacturing capacity starting in 2022. The company expanded injectable filling and packaging at facilities in Denmark and acquired additional capacity through its Catalent acquisition in 2024. Eli Lilly made parallel investments for tirzepatide, including new facilities in North Carolina and expanded Indiana operations.

The result was a step-change in available supply. By late 2024, tirzepatide production was running at levels sufficient to cover demand across all dosage strengths; semaglutide followed in early 2025. With reliable supply, the statutory justification for large-scale compounded production disappeared.

The Litigation That Tried to Preserve the Status Quo

In October 2024, the Outsourcing Facilities Association filed suit in federal court challenging the FDA's determination that the tirzepatide shortage was resolved. The association argued that real-world access was still constrained at certain dosage levels and that the FDA's decision was procedurally deficient.

The lawsuit delayed full enforcement for several months but ultimately did not reverse the shortage determination. By the time the case was resolved on procedural grounds, market conditions — accelerating brand-name production, falling prices, and expanding authorized telehealth distribution — had made the policy question less commercially urgent.

What Happened to Compounded Production

It's important to understand that not all compounding became illegal. 503A personalized compounding — where a pharmacy compounds a medication for a specific named patient based on a documented clinical need that the commercial product cannot meet — is still legal and appropriate in certain circumstances. What ended was the mass-production model that had been feeding the telehealth boom.

What This Means for Current Access

For patients who had been accessing compounded semaglutide through mass-market telehealth, the practical path forward is usually one of three: transition to brand-name Wegovy through an authorized NovoCare partner at the new subscription pricing, evaluate oral semaglutide (Rybelsus for diabetes or oral Wegovy for weight management), or work with a prescriber to determine whether documented clinical need qualifies for personalized 503A compounding. See our related reporting on the $349 Wegovy price cut timeline and how oral Wegovy compares to the injection.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.